These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 35039353

  • 41. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.
    Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
    [Abstract] [Full Text] [Related]

  • 42. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 43. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N, Thomas S, Bindal P, Shukla P, Hegde U.
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [Abstract] [Full Text] [Related]

  • 44. A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma.
    Salangsang J, Sapkota S, Kharel S, Gupta P, Kalla A.
    Cureus; 2023 Feb; 15(2):e35276. PubMed ID: 36825072
    [Abstract] [Full Text] [Related]

  • 45. Rare, but Severe: Vasculitis and Checkpoint Inhibitors.
    Lindner AK, Gruenbacher G, Schachtner G, Thurnher M, Pichler R.
    Eur Urol Focus; 2020 May 15; 6(3):609-612. PubMed ID: 31072806
    [Abstract] [Full Text] [Related]

  • 46. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN, Kudinov AE, Dulaimi E, Boumber Y.
    BMC Cancer; 2019 Apr 24; 19(1):379. PubMed ID: 31018834
    [Abstract] [Full Text] [Related]

  • 47. New-Onset Autoimmune Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Association With Pembrolizumab Therapy and Long Term Follow-Up: Case Report.
    Pachpande V, Mullangi S, Lekkala MR, Patel A.
    Cureus; 2022 Apr 24; 14(4):e24479. PubMed ID: 35651416
    [Abstract] [Full Text] [Related]

  • 48. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 24; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 49. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug 24; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 50. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH, Kuo J, Budiman A, Christie H, Ali S.
    Melanoma Res; 2017 Apr 24; 27(2):152-154. PubMed ID: 27776019
    [Abstract] [Full Text] [Related]

  • 51. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
    Bas O, Ozbek A, Guven D, Aktepe O, Kılıc L, Kertmen N, Erman M.
    J Oncol Pharm Pract; 2020 Jul 24; 26(5):1230-1233. PubMed ID: 31735133
    [Abstract] [Full Text] [Related]

  • 52. Anti-PD-1 Therapy-Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma.
    Samoa RA, Lee HS, Kil SH, Roep BO.
    Diabetes Care; 2020 Sep 24; 43(9):2293-2295. PubMed ID: 32616607
    [Abstract] [Full Text] [Related]

  • 53. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
    Kotwal A, Haddox C, Block M, Kudva YC.
    BMJ Open Diabetes Res Care; 2019 Sep 24; 7(1):e000591. PubMed ID: 30899528
    [Abstract] [Full Text] [Related]

  • 54. Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound.
    Harnden K, Di Matteo A, Howell K, Mankia K.
    BMJ Case Rep; 2024 Apr 24; 17(4):. PubMed ID: 38663895
    [Abstract] [Full Text] [Related]

  • 55. Atezolizumab induced new-onset type 1 diabetes mellitus.
    de Carlos J, Zabalza L, Garcia J, Marti M, Ayarza-Marien X, Yoldi J.
    J Oncol Pharm Pract; 2023 Jul 24; 29(5):1268-1270. PubMed ID: 36635950
    [Abstract] [Full Text] [Related]

  • 56. Pembrolizumab-Induced Ketoacidosis: A Case Report.
    Guimarães F, Polishchuk N, Almeida Martins C.
    Cureus; 2024 Jul 24; 16(7):e65906. PubMed ID: 39219904
    [Abstract] [Full Text] [Related]

  • 57. Immune checkpoint inhibitor-associated myocarditis and fulminant type I diabetes in a patient with metastatic non-small cell lung cancer.
    Davis BM, Fordjour I, Chahin M, Guha A.
    BMJ Case Rep; 2023 Aug 16; 16(8):. PubMed ID: 37586752
    [Abstract] [Full Text] [Related]

  • 58. Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy.
    Luong B, Koch G, Trivedi K, Ramachandran K.
    Am J Ther; 2023 Aug 16; 31(4):e474-e475. PubMed ID: 38976534
    [No Abstract] [Full Text] [Related]

  • 59. IgA nephropathy after pembrolizumab therapy for mesothelioma.
    Wang R, Das T, Takou A.
    BMJ Case Rep; 2020 Nov 30; 13(11):. PubMed ID: 33257374
    [Abstract] [Full Text] [Related]

  • 60. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D, Guan Y, Liu M, He S, Zhao W, Yin B, Liang J, Li Y, Wang J.
    Front Immunol; 2021 Nov 30; 12():608292. PubMed ID: 34135884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.